4565 — Nxera Pharma Co Share Price
0.000.00%
Last trade - 00:00- ¥76bn
- ¥108bn
- ¥29bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 41.37 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.11 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.96% | ||
| Return on Equity | -7.15% | ||
| Operating Margin | -18.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 8,842 | 17,712 | 15,569 | 12,766 | 28,835 | 35,410 | 39,373 | 24.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -95.01 | +3673.67 | -63.94 | n/a | n/a | n/a | +491.22 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.
Directors
- Shinichi Tamura CHM (72)
- Malcolm Weir VCH (61)
- Chris Cargill CFO (38)
- Kazuhiko Yoshizumi EVP (67)
- Tim Tasker EVP (56)
- Tadayoshi Yasui EVP (61)
- Kuniaki Kaga IND (69)
- Noriaki Nagai IND (63)
- David Roblin IND (54)
- Rolf Soderstrom IND (55)
- Tomohiro Toyama IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 22nd, 1990
- Public Since
- July 29th, 2004
- No. of Shareholders
- 24,082
- No. of Employees
- 374
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 89,900,943
- Address
- Midtown East, 9-7-2, Akasaka, MINATO-KU, 107-0052
- Web
- https://www.nxera.life/
- Phone
- +81 352103290
- Auditors
- Ernst & Young ShinNihon LLC
Upcoming Events for 4565
Dividend For 4565.T - 0.0000 JPY
Q2 2025 Nxera Pharma Co Ltd Earnings Release
Similar to 4565
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Nxera Pharma Co share price?
As of Today at 22:23 UTC, shares in Nxera Pharma Co are trading at ¥848. This share price information is delayed by 15 minutes.
How has the Nxera Pharma Co share price performed this year?
Shares in Nxera Pharma Co last closed at ¥848 and the price had moved by -41.52% over the past 365 days. In terms of relative price strength the Nxera Pharma Co share price has underperformed the Nikkei 225 Index by -36.13% over the past year.
What are the analyst and broker recommendations for Nxera Pharma Co?
The overall consensus recommendation for Nxera Pharma Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Nxera Pharma Co dividend yield?
Nxera Pharma Co does not currently pay a dividend.
Does Nxera Pharma Co pay a dividend?
Nxera Pharma Co does not currently pay a dividend.
When does Nxera Pharma Co next pay dividends?
Nxera Pharma Co does not currently pay a dividend.
How do I buy Nxera Pharma Co shares?
To buy shares in Nxera Pharma Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nxera Pharma Co?
As of the previous close price of ¥848, shares in Nxera Pharma Co had a market capitalisation of ¥76bn.
Where are Nxera Pharma Co shares listed?
Here are the trading details for Nxera Pharma Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4565
What kind of share is Nxera Pharma Co?
Based on an overall assessment of its quality, value and momentum Nxera Pharma Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nxera Pharma Co share price forecast for 2025?
The analyst consensus target price for shares in Nxera Pharma Co is ¥1,855. That is 118.75% above the last closing price of ¥848.
Analysts covering Nxera Pharma Co currently have a consensus Earnings Per Share (EPS) forecast of ¥8 for the next financial year.
Find out moreWhat is the trend in the Nxera Pharma Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nxera Pharma Co. Over the past six months, its share price has underperformed the Nikkei 225 Index by -18.53%.
As of the last closing price of ¥848, shares in Nxera Pharma Co were trading -28.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nxera Pharma Co PE Ratio?
The Nxera Pharma Co PE ratio based on its reported earnings over the past 12 months is 41.37. The shares last closed at ¥848.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nxera Pharma Co?
Nxera Pharma Co's management team is headed by:
- Shinichi Tamura - CHM
- Malcolm Weir - VCH
- Chris Cargill - CFO
- Kazuhiko Yoshizumi - EVP
- Tim Tasker - EVP
- Tadayoshi Yasui - EVP
- Kuniaki Kaga - IND
- Noriaki Nagai - IND
- David Roblin - IND
- Rolf Soderstrom - IND
- Tomohiro Toyama - IND